Search

Your search keyword '"Waked, Imam"' showing total 476 results

Search Constraints

Start Over You searched for: Author "Waked, Imam" Remove constraint Author: "Waked, Imam"
476 results on '"Waked, Imam"'

Search Results

101. Aiming at the global elimination of viral hepatitis:challenges along the care continuum

104. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients

106. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

109. LBP-08-The World’s Largest Hepatitis C Screening Program in Egypt

110. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

111. Evolution of Hepatic Fibrosis in 3,460 Untreated Hepatitis C Patients Without Cirrhosis

113. Analysis of long-term endoscopic surveillance during follow-up after variceal sclerotherapy from a 13-year experience

114. Hepatitis C infection in Egypt: prevalence, impact and management strategies

115. Hepatitis C treatment: where are we now?

116. Hepatitis C in Egypt – past, present, and future

118. Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

120. High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection

122. Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study

123. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

124. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience

126. Doxorubicin-Loaded Nanoparticles for Patients with Advanced Hepatocellular Carcinoma after Failure of Sorafenib: RELIVE, a Phase-3 Trial

127. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4

128. Health: redefined

129. Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]

130. Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum

131. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience

133. The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy

137. High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.

138. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.

139. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients

147. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection:a randomised study

149. Association of Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide polymorphisms with hepatitis C virus persistence among Egyptians.

150. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.

Catalog

Books, media, physical & digital resources